Daily Stock List
Far East Energy Corp. (FEEC)
Greenbackers reported recently on Far East Energy Corp. (FEEC), SmarTrend Newsletters, UltimatePennyStock did earlier, and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Founded in 2000, Far East Energy Corp., via their subsidiaries,focuses on coalbed methane exploration and development in China.Far East Energy holds, by way of production sharing contracts (PSCs), interests in three of China’s largest coalbed methane fields. These are the 485,000 acre Shouyang Block in Shanxi Province; the 573,000 acre Qinnan Block in Shanxi Province; and the 265,000 acre Enhong and Laochang regions in Yunnan Province. Listed on the OTCQB, the Company has their headquarters in Houston, Texas, and offices in Beijing, and Taiyuan City, China.
As of December 31, 2012, Far East Energy had estimated net proved gas reserves of 51.3 MMcf, and estimated total net probable reserves of 392.4 MMcf.The Companyis the operator under a PSC entered into with CUCBM to develop the Shouyang Block in the Shanxi Province.Far East Energy is the operator under a PSC with China National Petroleum Company (CNPC), the successor to CUCBM, to develop the Qinnan Block in the Shanxi Province.
On January 25, 2002, Far East Energy entered into a PSC with CUCBM to develop two areas in the Yunnan Province. One is the Enhong area, which covers approximately 145,198 acres. The other is the Laochang area, which covers approximately 119,772 acres. Far East Energy is the operator under the PSC.
Last week, Far East Energy announced that nine new wells have begun drilling in the 21 days since the last 2013 drilling program update release issued on Thursday, June 27. This brings to 52 the total number of wells spudded this year; 25 are production wells and 20 of those production wells have reached total depth, with 12 of those 20 having been fraced as of July 17. Another well was scheduled to be fraced on July 18.
In addition, eight more wells reached total depth, and 15 wells have now been fraced as the Companynears the halfway point in the first of their planned 2013 frac campaigns. At present, there are 29 rigs in the field.
Far East Energy Corp. (FEEC), closed Thursday’s trading session at $0.154, up 2.67%, on 344,698 volume with 47 trades. The average volume for the last 60 days is 1,371,766 and the stock's 52-week low/high is $0.038/$0.25.
Legend Oil and Gas, Ltd. (LOGL)
SmarTrend Newsletters reported earlier on Legend Oil and Gas, Ltd. (LOGL), and we highlight the Company today, here at the QualityStocks Daily Newsletter.
Headquartered in Seattle, Washington, Legend Oil and Gas, Ltd. is an oil and gas exploration, development and production company. Their focus is to acquire producing and non-producing oil and gas right interests and develop oil and gas properties that they own or have a leasehold interest in. The Company also anticipates pursuing the acquisition of leaseholds and sites within other geographic regions that meet their general investment guidelines and targets.
Legend Oil and Gas’ oil and gas property interests are in Western Canada (in Berwyn, Medicine River, Boundary Lake, and Wildmere in Alberta, and Clarke Lake and Inga in British Columbia). Furthermore, their interests are in the United States (in the Piqua region of Kansas).
Pertaining to the Piqua Project, it is in Woodson County. Its size is 1,040 acres of net mineral leases. Production is 18 BOPD, and the number of active wells is 44. The well type is oil and water injection and the Company's freehold royalty is 12.5 percent. Legend intends to concentrate on their Kansas asset base this year.
Concerning the Company’s Canadian Projects, the Canadian assets acquired by Legend Oil and Gas are administered within their wholly owned subsidiary Legend Energy Canada Ltd. (LECL). These assets contain oil and gas properties presently producing close to200 BOE/d. The properties contain a mix of 37 percent oil and natural gas liquid production, and 63 percent gas production. The majority of the properties are in the Province of Alberta. Almost 41 percent of the total sales are taken from British Columbia (B.C.), directly west of Alberta.
Total Canadian production is contained within nine production entities. In addition, 82 percent of the total is contained within the Berwyn, Medicine River and Wildmere properties in Alberta and Clarke Lake in B.C. The majority of the Company’s operational duties are outsourced to consultants and independent contractors. This includes for drilling, maintaining and operating their wells.
Earlier this month,Legend Oil and Gasannounced that they successfully closed a convertible debenture financing in the principal amount of US $900,000 on terms that are favorable to the Company. Hillair Capital Investments LP is the sole financial partner on this financing.
Mr. Marshall Diamond-Goldberg, President of Legend Oil and Gas, stated, "We have been working diligently to attract a strong financial partner who understands the potential upside contained within the Legend asset base. The successful closing of this financing provides the Company with sufficient capital in hand to proceed with its drilling program in Kansas, as well as the capital necessary to move forward with the low cost and high impact opportunities identified on its Canadian assets acquired in 2011."
Legend Oil and Gas, Ltd. (LOGL), closed at $0.10, up 21.80%, on 3,000 volume with 6 trades. The average volume for the last 60 days is 80,681 and the stock's 52-week low/high is $0.03/$0.142.
Voip-Pal.com, Inc. (VPLM)
UndiscoveredEquities, SmallCapVoice, and TheSUBWAY reported previously on Voip-Pal.com, Inc. (VPLM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Voip-Pal.com, Inc.is a technical leader in the broadband Voice-over-Internet Protocol (VoIP) market with the ownership and development of a portfolio of leading edge VoIP Patent Applications. Additionally,via theirretail website, www.PlatinumPhone.com, the Company is a provider of local and long-distance VoIP telephone services for next generation devices; these include smartphones, tablets and cell phones. Voip-Pal.com lists on the OTC Pink Current Information. The Company is based inBellevue, Washington.
Through Voip-Pal.com’s agreement to acquire Digifonica (International) Ltd., Digifonica representstheir enterprise as owners of an extensive and wide-ranging VoIP patent portfolio containing pioneering proprietary VoIP technologies.Included in the assets owned by Digifonica are Patent Pending Applications including Lawful Intercept: Routing, Billing, and Rating engine (RBR); Mobile Gateway; Enhanced 911, as well as Advanced Interoperability Solutions.
Presently, Voip-Pal.com is developing, testing, and administrating the patent process to eventually license or sell the patents upon issuance.The Company expects that the patent application portfolio will contribute to substantial future revenue growth for Voip-Pal.com as the projection is that the number of mobile VoIP subscribers will reach 410 million by 2015.
Voip-Pal.com’s www.PlatinumPhone.com was launched in October of 2012. The basis of this website is upon a Voip-Pal owned proprietary softswitch Framework designed to integrate the Company’s Patent Applications. Voip-Pal provides pay as-you-go international calling services. This includes a free PC Dialer and a free smartphone app for the Android.
In development is the smartphone app for the iPhone and iPad and a Platinum Suite package that will bundle airtime minutes with a free one year subscription to PlatinumPhone Guard™, an innovative antivirus program for the Android smartphone.
This week,Voip-Pal.com announced the successful completion of the physical transfer of shares between the Company and Digifonica (International) Ltd. The share transfer request was started following the fulfillment of the Share Purchase Acquisition Agreement announced earlier this month. Successful completion of the transfer of these shares was the final step in the acquisition process. Digifonica is now a wholly owned subsidiary of Voip-Pal.com.
Voip-Pal.com, Inc. (VPLM), closed Thursday’s trading session at $0.0765, up 10.87%, on 2,463,202 volume with 48 trades. The average volume for the last 60 days is 1,352,575 and the stock's 52-week low/high is $0.0055/$0.105.
Pervasip Corp. (PVSP)
Stock Legends and PennyStocks24 reported recently on Pervasip Corp. (PVSP), SmallMovesBigGains did earlier, and we highlight the Company today, here at the QualityStocks Daily Newsletter.
Pervasip Corp. is a provider of video and voice over Internet Protocol, or VoIP, telephony services. The nature of the Company’s technology is cloud-based computing.Pervasip delivers VoIP and video telephone service anywhere globally that has a stable broadband connection.The Company sells under the brand name of VoX Communications, VoX or VoX Mobile. Pervasip has their corporate headquarters in White Plains, New York.
The Company has transformed their VoIP service to a downloadable digital product. This product,unitedwith their fully-automated back office, allows Pervasip to sell their voice, video and messaging services instantly to a large array of mobile devices worldwide.The Company has begun selling calling cards, submitted their mobile VoIP app to the Apple app store, and put in place new marketing initiatives in 2013.In addition, they instituted a plan focused on achieving positive cash flow from operations by Q1 2014.
Pervasip featuresaninnovative combination of high quality voice services, flexible back-office capabilities and automated provisioning systems. These enable a fast turn-up for application users who are looking for a second mobile phone line or low-cost international calling, without using any voice-plan minutes from their mobile phone carrier.Recently, the Company entered the mobile VoIP services and applications arena so their VoIP can utilize any 3G/4G or WiFi connection.
This month,Pervasip announced that their VoX Mobile VoIP App for Android phone and tablets reached the number one ranked position in the Google Play Store when searching for the keyword VoIP.The Companymarkets their VoIP products via their wholly-owned subsidiary, VoX Communications.
VoX,using their nationwide VoIP network, offers scalable and reliable broadband voice, origination and termination services to cable, wireless and wireline operators, as well as enhanced VoIP telephone service to the small business and residential markets.The VoX service can undergo deployment and customization for each customer, remotely from a central location.
Pervasip Corp. (PVSP), closed Thursday’s session at $0.0022, down 15.38%, on 6,407,343 volume with 45 trades. The average volume for the last 60 days is 7,672,553 and the stock's 52-week low/high is $0.0013/$0.016.
Sustainable Environmental Technologies Corp. (SETS)
AllPennyStocks reported previously on Sustainable Environmental Technologies Corp. (SETS), and we highlight the Company today, here at the QualityStocks Daily Newsletter.
Sustainable Environmental Technologies Corp. (SETS), through their subsidiaries, acquires, develops and markets strategic technologies that responsibly and economically solve environmental issues. The Companyprovides patented treatment, recovery, reclamation, and re-injection services for produced water; and energy solutions in the U.S.In addition, SETS offers design, construction, management, operation, and maintenance services. They also offer equipment manufacturing services for industrial and municipal sectors. The Company is based in Upland, California.
Theirmainproducts include the Centerline SWD System, and the DynIX technology. The Company’stechnologies deliver vital resources for business operations while reducing their customers' environmental impact and conserving essential and diminishing resources. SETS’ offering includes treatment, recovery, reclamation and re-injection services for produced water from oil and gas production. Their offerings also include ultra-efficient tri-gen systems that offer combined cooling, heating, and power generation with the added capability of water production from a single energy source.
The basis of the Company’sCenterline SWD™ facilities are on the strategic utilization and placement of patented and best in class technology that maximize the purification and separation processes. This model allows for the separation of 99 percent of any remaining oil residue in the produced water. It also allows for the proper cleaning and preparation of the water for either deep injection into the earth or reselling of the cleaned and treated water for frak and other oil field processes.
SETS’DynIX is a fixed bed dynamic flow ion exchange system. The design of it was originally specially for signature characteristics of Coal Bed Methane (CBM) produced water and deployed in Wyoming’s Powder River Basin. The Company’s proprietary technology has significantly reduced the waste stream to less than 4 percent of treated water volume.
In addition, the Company’s solutions include Blue Bench. Pro Water, LLC, by way of their Blue Bench Deep Injection Well (DIW), has an established customer base that generates positive monthly cash flow. This will allow SETS to fund further technology acquisitions. Pro Water is scheduled to start construction of a full research and development laboratory. Upon completion, this multi-acre facility will serve as a showplace for potential customers and a technology incubator that cultivatesnew and upcoming ventures that can be proven and then brought into SETS.Blue Bench is on 10 acres, in Utah. It has a daily injection capacity of 10,000 barrels per day.
Sustainable Environmental Technologies Corp. (SETS), closed today’s trading at $0.08, up 14.12%, on 41,900 volume with 5 trades. The average volume for the last 60 days is 33,517 and the stock's 52-week low/high is $0.0701/$0.68.
U.S. Energy Corp. (USEG)
SmarTrend Newsletters reported last week on U.S. Energy Corp. (USEG), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Based in Riverton, Wyoming, U.S. Energy Corp. is a natural resource exploration and development company that lists on the NASDAQ Capital Market. The Company’sprincipal focus is on the exploration and development of their oil and gas assets. The Company has a varied portfolio of drilling prospects in the Williston Basin of North Dakota and Montana. They also have drilling prospects in the Eagle Ford Shale and Buda Limestone formations in South Texas, as well as the shallow Wilcox formation in East Texas.
U.S. Energy’s main emphasis is in the natural resources sector, including oil and gas and renewable energy.Additionally, U.S. Energy owns the Mount Emmons molybdenum deposit in west-central Colorado. The Mount Emmons Project is a proposed mining operation situated in Gunnison County west of Crested Butte, Colorado. The belief is that this world class deposit is one of the largest and purest molybdenum deposits in the world.
Last week, U.S. Energy provided an operational update. Concerning South Texas – the Buda Limestone formation,the Beeler #2H well in the Booth-Tortuga acreage block in Dimmit County, Texas produced approximately 45,000 gross BOE during the first 60 days of production, or an average of 750 gross BOE/D. U.S. Energy participates in approximately 10,140 gross acres that are prospective for the Buda formation. The Company has an approximate 30 percent working interest and an approximate 22.8 percent net revenue interest in the acreage.
Pertaining to theWilliston Basin, North Dako a - theBakken and Three Forks formations,the Caper 1-15-22H (Bakken Formation) well was completed with 35 fracture stimulation stages in mid-June with an early peak 24-hour production rate of 2,063 BOE/D.The Rogers 1-12 #1TFH (Three Forks Formation) well was completed with 35 fracture stimulation stages in mid-June with an early peak 24-hour production rate of 825 BOE/D.
The Dobias 152-103-32-29-#1H (Bakken Formation) well was completed with 35 fracture stimulation stages in the second week of July with an early peak 24-hour production rate of 1,399 BOE/D. Moreover, in East Texas – the Wilcox Sand formation,the Fender #1 well in Anderson County, Texas was drilled in April, 2013.
Today,U.S. Energy announced the extension and the execution of amendments to their $100 million senior secured revolving credit facility with Wells Fargo Bank, National Association.On July 23, 2013, U.S. Energy entered into a second amendment to their senior secured revolving credit facility, dated July 30, 2010, as amended.The Company, to date, has $10.0 million outstanding under the facility, with an additional $15.0 million available under the Senior Credit Agreement.
U.S. Energy Corp. (USEG), closed Thursday’s session at $2.16, up 1.41%, on 163,959 volume with 311 trades. The average volume for the last 60 days is 119,074 and the stock's 52-week low/high is $1.45/$2.55.
Ressources Appalaches (APP.V)
Greenbackers reported previously on Ressources Appalaches (APP.V), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Listed on the TSX Venture Exchange, Ressources Appalaches focuses on thediscovery and development of deposits of base and precious metals in Canada. The Company’s expertise is concentrated towards the Appalachian geological formation in Quebec and Nova Scotia.They explore for gold, uranium, copper, lead, and zinc deposits in theseregions. Founded in 1994, Ressources Appalaches has their headquarters in Rimouski, Quebec.
The Company hasapproximately 12 mineral properties in different stages of development. Theirchief property includes the Dufferin gold project in the Province of Nova Scotia.The Dufferin Mine Project planning process is now shifting to the path of production. Ressources Appalaches is the sole owner of the Dufferin Mine (100 percent).
The Dufferin Mine has a mining lease in good standing, a 300 tonnes per day plant, a tailings facility, and a gravity and flotation process. In 2012, Ressources Appalaches made astrategicacquisitionof the East Dufferin claimadjoining the anticline structure associated to the Dufferin deposit. This extends access to the anticline structure towards the East for8.4 kilometers.
In 2013, the Company successfully completed the due diligence related to a gold loan financing needed to recommence gold production. In addition, they submitted an Industrial Approval Application for a 300TPD Gravity and Flotation Milling Operation.
Yesterday,Ressources Appalaches reported on the progress of their Dufferin gold mine project since the announcement of the loan financing of US $10M secured. Achievements to date include completing soft-starts and the testing of all crushing circuit components.Underground rehabbing continues to the second level with water, air and dewatering service lines made operational. Additionally, theprimary and secondary underground ventilation is operational.
Heavy equipment and material required for site preparation was acquired and delivered. The Company also began the acquisition of the long-lead items needed to restart gold production. Furthermore, they began the vetting of 462 applications for the remaining approximately 60 staffing positions needed to resume production later this year. Moreover, they made a Board nomination of Mr. Jose Oro as Director.
Ressources Appalaches (APP.V), closed Thursday’s trading session at $0.095, even for the day, on 104,900 volume. The stock's 52-week low/high is $0.05/$0.12.
VMS Ventures, Inc. (VMS.V)
Agoracom and AllPennyStocks reported previously on VMS Ventures, Inc. (VMS.V), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
VMS Ventures, Inc.concentrates principallyon acquiring, exploring and developing copper-zinc-gold-silver massive sulphide deposits in the Flin Flon-Snow Lake VMS Belt of Manitoba.VMS Ventures owns approximately 27.5 percent of North American Nickel, Inc. (NAN.V).VMS chiefly explores for copper, zinc, nickel, gold, and silver ores. Their principal property includes the Reed Lake project located southwest of Snow Lake, Manitoba.
VMS Ventures has their corporate headquarters in North Vancouver, British Columbia.The Company previously went by the name Rare Earth Metals Corp. They changed their corporate name to VMS Ventures, Inc. in January of 2007. The Company’s shares trade on the TSX Venture Exchange.
The Company's VMS project property portfolio consists of the Reed Copper Project, which is scheduled for production in Q4-2013. VMS Ventures owns 30 percent of the Reed Copper Project and is carried to production. Hudbay Minerals, Inc. (HBM.TO) (HBM) owns 70 percent and is the Operator.VMS Ventures’ property portfolio also consists of the Copper Project, the McClarty Lake Project, the Sails Lake Project, the Puella Bay Project and the Morton Lake Project.
Outside of the Snow Lake camp, VMS Ventures holds massive sulphide prospective properties near the past producing Fox Lake and Ruttan copper-zinc mines, close to the Lynn Lake and Leaf Rapids communities in northern Manitoba. The Company has also optioned the Black Creek property in the Sudbury mining camp (Province of Ontario).The Black Creek property consists of 63 mining claims (93 mining claim units).
Yesterday,VMS Ventures updated shareholders on progress made during June 2013 at the Reed Copper Project, near Flin Flon Manitoba.Highlights at the Reed Copper Project include the ramp development advancing a further 142meters, taking the total development to 819meters for the project so far. The escape and ventilation raises from surface and camp expansion were completed. In addition, theconstruction of the diesel fuel and surface oil containment areas was completed. The Reed Copper Project continues on schedule. It is forecast to be completed on budget by the end of March 2014.
VMS Ventures, Inc. (VMS.V), closed Thursday’s trading session at $0.1750, up 6.06%, on 36,500 volume. The stock's 52-week low/high is $0.15/$0.28.
Epazz Inc. (EPAZ)
The QualityStocks Daily Newsletter would like to spotlight Epazz Inc. (EPAZ). Today, Epazz Inc. closed trading at $0.0018, up 5.88%, on 52,738,716 volume with 293 trades. The stock’s average daily volume over the past 60 days is 7,735,850 and its 52-week low/high is $0.0006/$0.045.
Epazz Inc. announced today that they have been working on a new product called "Human Power," a new mobile power device not directly in line with the company's core business and therefore strategically optimal for being their second spin-off endeavor. Moreover, this spin-off, to take place after the will be a laboratory for EPAZ to refine their spin-off implementation procedures post Project Flex, generating more stock opportunities for shareholders.
Epazz Inc. (EPAZ) is a leading cloud-based software company focused on providing customized cloud applications to Fortune 500 enterprises, government agencies, and higher education institutions. Targeting a strong growth industry, the company is rapidly expanding via strategic acquisitions, a full suite of in-house products and services, and diversified streams of income.
The fully reporting company is demonstrating substantial performance in a competitive industry, completing six acquisitions while maintaining organic subsidiary growth. In the last three years, Epazz revenues have increased by more than 300%. The company will produce its first spinoff with “Project Flex” and issue a stock dividend to shareholders of record on the record date.
As an enterprise-wide software company, Epazz is adeptly serving the increasing information technology demand of the 21st century. According to IDC, the premiere global market intelligence firm, the IT cloud services industry is expected to grow from $40 billion to $100 billion in just four years. Management anticipates the company’s growth to accelerate as the market for its technology solutions continues to expand.
Epazz BoxesOS™ v3.0 is the complete business web-based software package for small to mid-size businesses, Fortune 500 enterprises, government agencies, and higher education institutions. The turnkey enterprise system, which includes content, integration, customization, and marketing services, provides many of the web-based applications organizations would have to otherwise buy separately. Disclaimer
Epazz Inc. Blog
Epazz Inc. News:
EPAZZ Announces Second Planned Spin-Off Project "Human Power" Mobile Power Device
Epazz Sets Stock Dividend Record Date for Project Flex Spin-Off
Epazz Reports 33 Percent Increase in Assets for 2012
Advaxis, Inc. (ADXSD)
The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXSD). Today, Advaxis, Inc. closed trading at $3.44, up 8.18%, on 12,577 volume with 37 trades. The stock’s average daily volume over the past 60 days is 8,258, and its 52-week low/high is $3.10/$19.375.
Advaxis Inc. announced an updated business outlook for 2013 today, including the development of its clinical strategy to advance its lead product candidate, ADXS-HPV, to registrational trials amid a strengthening financial position and additional, encouraging ancillary data. Chief among the milestones anticipated is progress on their three applications for Orphan Drug Designations with the FDA on ADXS-HPV in three human papillomavirus (HPV)-associated indications: invasive cervical cancer, anal cancer, and head and neck cancer.
Advaxis, Inc. (ADXSD) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.
The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer
Advaxis, Inc. Company Blog
Advaxis, Inc. News:
Advaxis Updates Business Outlook for 2013
Advaxis Announces ADXS-cHER2 Demonstrates Significant Survival Advantage in Ongoing Canine Osteosarcoma Study
Advaxis Announces Appointment of New Member to Its Board of Directors
Rafarma Pharmaceuticals, Inc. (RAFA)
The QualityStocks Daily Newsletter would like to spotlight Rafarma Pharmaceuticals, Inc. (RAFA). Today, Rafarma Pharmaceuticals, Inc. closed trading at $0.68, up 4.62%, on 5,600 volume with 5 trades. The stock’s average daily volume over the past 60 days is 54,624, and its 52-week low/high is $0.041/$0.98.
Rafarma Pharmaceuticals, Inc. announced a cooperative research and development effort today with Christian Albrecht University in Kiel, whose roll-call of Nobel Prize winners speaks for the institution's reputation all by itself, on some key initial, as well as future projects. The partnership will seek to develop innovative Liposomal forms, anti-cancer and anti-tuberculosis drugs with certain targeted pharmacokinetic characteristics, as well as products with higher bioavailability (thereby increasing absorption rates) through modification of biopharmaceutical characteristics, and represents a compelling marriage of a top-level research university and a RAFA's state-of-the-art pharmaceutical production facilities.
Rafarma Pharmaceuticals, Inc. (RAFA) is a multiproduct pharmaceutical company specializing in the production of generic antibiotics and specialty pharmaceuticals, including its own proprietary products approved by the ministry of health. Rafarma stands as one of the most ambitious projects in recent medical history, having constructed the most technologically advanced pharmaceutical plant in Russia.
Based in Terbuny, Lipetsk region, Russia, Rafarma possesses a unique niche in the burgeoning pharmaceutical market and is poised to become a major player in the international drug industry. The company was established under the auspices of the Foundation to Support Health Care and has been approved by the Ministry of Health.
Rafarma recently received the general license for pharmaceutical products and began manufacturing three new products: Sodium Para-Aminosalicilate, Ibuprofen, and Betagistin. Receiving the general license was one of the final steps the company needed to open its new plant in Terbuniv, and Rafarma has been named one of only four national strategic pharmaceutical suppliers to the Russian Federation.
Advances in health care science, medicine, and technology have increased the general life expectancy of Eastern European citizens steadily over the past decade. Elderly citizens, which comprise the largest portion of the pharmaceuticals market, have bolstered demand for pharmaceuticals nationwide. Rafarma is well positioned to capitalize on the expanding industry with its strong relationships and state-of-the-art production facility. Disclaimer
Rafarma Pharmaceuticals, Inc. Company Blog
Rafarma Pharmaceuticals, Inc. News:
Rafarma Announces Cooperative Effort With Christian Albrecht University in Kiel, Germany
Rafarma Pharmaceuticals Operational Subsidiary Introduces New Board of Directors
Rafarma Pharmaceuticals Enters Into New Exclusive Production Contract With JSC F-Synthesis to Produce Anti-Cancer Drug Imatinib
VentriPoint Diagnostics Ltd. (VPTDF)
The QualityStocks Daily Newsletter would like to spotlight VentriPoint Diagnostics Ltd. (VPTDF). Today, VentriPoint Diagnostics Ltd. closed trading at $0.085, on 10,722 volume with 3 trades. The stock’s average daily volume over the past 60 days is 15,790, and its 52-week low/high is $0.055/$0.1595.
VentriPoint Diagnostics Ltd. was pleased to announced today that the cardiology group from the University of Chicago, led by Dr. Roberto Lang, has published a key paper highlighting first-in-humans, clinical study work using Ventripoint's VMS™ product, in what is the premiere journal in the field of echocardiography. The analysis is clear, the VPTDF product yields "feasible, accurate, and reproducible" Knowledge-Based Reconstruction results that is a god-send for patients with Pulmonary Arterial Hypertension.
VentriPoint Diagnostics Ltd. (VPTDF) leverages knowledge-based techniques to make heart analysis more convenient and less expensive. Having already installed multiple VMS™ analysis systems for heart testing in leading cardiac centers in Europe, Canada and the United States, the company is currently focused on expanding the applications of its technology beyond congenital heart disease in adults and children.
VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. The company designed its analysis system to be used for all major heart diseases, including pulmonary hypertension, cardiovascular disease, and heart failure. Canada and Europe (CE Mark) have granted approval for the sale of the VMS™ diagnostic tool, and VentriPoint is pursuing the US-FDA approval through the 510(k) process.
The company’s VMS™ analysis systems eliminate all the disadvantages of an MRI scan, including a long wait list, the one-hour scan time, the claustrophobic environment, the requirement of a general anesthetic for children, the lengthy heart analysis process, and the need for a second trip to the hospital. Offering better efficiency and cost savings, VMS™ offers the healthcare industry a superior method of heart visualization.
The management team executing VentriPoint’s business strategy retains extensive experience in both healthcare technology and business development. Many expansion opportunities exist for the company’s technology with a total market potential exceeding $1 billion. As a leader in the clinical diagnostics market, the company is well positioned to meet the well-defined clinical need for efficient, accurate, and inexpensive heart analysis. Disclaimer
VentriPoint Diagnostics Ltd. Company Blog
VentriPoint Diagnostics Ltd. News:
University of Chicago Publishes First Results Using Ventripoint Heart Analysis System in Pulmonary Arterial Hypertension in Prestigous Medical Journal
VentriPoint Announces Closing of Private Placement and Corporate Update
Ventripoint Announces New Vice-President of Sales and Marketing
Epazz has made headlines this week following the announcement of several exciting updates about its products and current stock status. Today, the company announced that it’s been working on a new project called “Human Power,” a new mobile powering device. Project Human Power is different from the company’s core software solutions, so it is positioned to become Epazz’s second spin-off.
Epazz is a cloud-based business software provider. Its software packages are designed to provide customized, web-based applications to small and mid-sized businesses, Fortune 500 companies, government agencies, and higher education institutions. With Project Human Power, Epazz is developing a product that allows iPhone users to power their mobile devices on the go, without an outlet or second battery.
Shaun Passley, Epazz’s CEO, remarked, “We believe Lunar represents a great opportunity to add value to our shareholders as well as provide an incentive for shareholders to stay with the company for the long term with the knowledge many more spin-offs will come in the future. Epazz’s spin-offs will give our shareholders opportunities to receive more stock through stock dividends of spin-off companies.”
For more information, please visit www.epazz.com
Advaxis, a clinical-stage biotech company developing the next generation of immunotherapies for cancer and infectious diseases, today issued an updated business outlook for 2013, highlighting its clinical initiatives to advance lead product candidate ADXS-HPV to registrational trials. The company also provided additional development and financial data.
“Earlier in the year, Advaxis stated that it would provide periodic updates to its business outlook and announced two overarching objectives for 2013: one, to advance our lead product candidate, ADXS-HPV, toward a registration development program and, two, to continue to significantly strengthen our financial position,” Thomas A. Moore, chairman and CEO of Advaxis, stated in the press release. “We have outlined the progress the Company has made on these two goals, as well as anticipated 2013 milestone events.”
Corporate Goals for 2013
- A determination for three applications for Orphan Drug Designations with the FDA for ADXS-HPV in three human papillomavirus (HPV)-associated indications: invasive cervical cancer, anal cancer, and head and neck cancer;
- Initiate dialogue with the FDA to discuss ADXS-HPV clinical development plans for the treatment of cervical cancer;
- Complete the elements required to file an Investigational New Drug (IND) application with the FDA for ADXS-PSA for the treatment of prostate cancer in the first half of 2014;
- Advance the canine osteosarcoma study into Phase 2 and expand to additional collaborative academic centers; and
- File an initial listing application for the NASDAQ Capital Market or NYSE AMEX.
ADXS also provided the following 2013 clinical program update:
- GOG 0265 safety run-in completed and study opened to the GOG group-wide
- Cervical Cancer Program – Final 12-month survival data from the Phase 2 cervical cancer trial announced at the 2013 ASCO Annual Meeting in Chicago in June. Preliminary efficacy data continue to show apparent prolonged survival, durable complete and partial tumor reductions, as well as stable disease with ADXS-HPV alone or in combination with cisplatin. ADXS has made substantial progress in analyzing the Phase 2 data and is planning a study to determine the best dose and dosing regimen to enhance efficacy without compromising the encouraging preliminary safety profile already observed. As of July 2013, 10 patients have been enrolled in the safety run-in portion of the study.
- Head and Neck Cancer Program – Cancer Research UK (CRUK) is funding a Phase 1/2 to evaluate the use of ADXS-HPV for the treatment of 27 patients with HPV positive head and neck cancer. As of July 2013, 16 patients have been enrolled in the study.
- Anal Cancer Program – The Brown University Oncology Group (BrUOG) is funding and coordinating a Phase 1/2 study of ADXS-HPV in 25 patients with HPV-associated anal cancer. As of July 2013, 3 patients have been enrolled in the study.
- Canine Osteosarcoma Study – Third dose cohort underway in the canine osteosarcoma study. In this trial, dogs that have undergone SOC for osteosarcoma, and over-express HER-2/neu in their tumors, are treated with ADXS-cHER2. Updated preliminary data show a significant survival advantage for 9 dogs that received SOC plus ADXS-cHER2 compared to 11 dogs, whose owners elected not to participate in the trial, but who were followed for survival. At this point in the study, 8 of 9 dogs treated with ADXS-cHER2 are alive (mean survival undefined), compared with 5 of 11 dogs in the control group (mean survival 265 days).
- Prostate Cancer Program – ADXS plans to file an IND with the FDA for ADXS-PSA in the treatment of prostate cancer in the first half of 2014. In June 2011, the company conducted a pre-IND meeting with the FDA to discuss the CMC, pharmacology, toxicology, and clinical plans for ADXS-PSA. The required toxicology studies have been completed and data analyses are ongoing.
Pertaining to business development, ADXS reports it has established several confidentiality agreements with biopharmaceutical companies for the license of ADXS-HPV in the U.S., Asia, and India. ADXS plans to pursue these negotiations to closure in the coming months.
The company has also entered into a confidentiality agreement with the animal health division of a major pharmaceutical company, among other potential licensing agreements with other companies, for the license of ADXS-cHER2.
ADXS stockholders in June approved the effect of a 1-for-25 reverse stock split and a decrease in authorized shares of the company to 25 million from 1 billion shares. The company intends to seek an uplisting to a national exchange in the near term, and said it believes that the combination of completing the reverse stock split and the contemplated uplisting could heighten the interest of the financial community in Advaxis, potentially increase investor interest in the company, and strengthen its financial health.
For more information visit: www.advaxis.com
Rafarma Pharmaceuticals just announced a cooperative research and development effort with Christian Albrecht University in Kiel on the following projects:
• The development of innovative Liposomal forms, anti-cancer and anti-tuberculosis drugs with certain targeted pharmacokinetic characteristics. The objective is to create parenteral medications based on non-dissolvable pharmaceutical substances using encapsulation and liposomes.
• The development of products with higher bioavailability (thereby increasing absorption rates) through modification of biopharmaceutical characteristics. The modifications are achieved by the creation of nano-crystals, which are formed through size reduction in the gas phase, as well as through synthetic crystallization.
These are only the first of several projects Rafarma is exploring in cooperation with Christian Albrecht University.
Rafarma CEO Dave Anderson stated, “This cooperative effort creates a synergy between a top-level research university and a state-of-the-art pharmaceutical production plant, which will open up many opportunities now and in the future for both Rafarma and Christian Albrecht University.”
Newly-appointed board member and CAU faculty member, Dr. Hartwig Steckel [the Director of the Department of Pharmaceutics and Biopharmaceutics (Institute of Pharmacy) at Christian Albrecht University], commented, “This relationship is extremely exciting and I look forward to progressing rapidly with RAFARMA-CAU joint developments.”
The University of Kiel, also known as Christian Albrecht University (CAU), was formally inaugurated in 1665. During its almost 350-year existence, the Christian-Albrechts-Universität in Kiel has given impetus and set new standards in many fields, including Pharmaceutical Technology. That much is clear from its roll-call of Nobel Prize winners. Some of the many recipients of this award to have taught at Kiel were Philipp Lenard (Physics 1905), Max Planck (Physics 1918) and Otto Diels (Chemistry 1950). Over the course of its history, the CAU has developed from a regional training academy to an internationally recognized university.
For more information on Rafarma, visit www.Rafarma.com
VentriPoint Diagnostics was pleased to announce today that the cardiology group from the University of Chicago, led by Dr. Roberto Lang, has published a paper entitled “Three-Dimensional Modeling of the Right Ventricle from Two-Dimensional Transthoracic Echocardiographic Images: Utility of Knowledge-Based Reconstruction in Pulmonary Arterial Hypertension” in the Journal of the American Society of Echocardiography (JASE), Volume 26, Issue 8, Pages 860-867, August 2013.
Knowledge-Based Reconstruction (KBR) is the scientific terminology for VentriPoint’s VMS™ product. The VMS™ has been approved for clinical use in Canada and Europe, but is currently for investigational use only in the United States.
The paper concludes: “Three-dimensional reconstruction of the RV endocardium from 2D transthoracic echocardiographic images obtained in patients with Pulmonary Arterial Hypertension (PAH), as accomplished by Knowledge-Based Reconstruction (KBR), is feasible, accurate, and reproducible.”
Dr. George Adams, CEO of Ventripoint, stated, “We congratulate the Chicago cardiology team on the publication of this first-in-humans, clinical study in the premiere journal in the field of echocardiography.”
JASE is the official publication of the American Society of Echocardiography, which is the largest international organization for cardiac imaging. The journal brings physicians and sonographers the most current clinical, scientific, legal, and economic information regarding the use of cardiac ultrasound. JASE’s original, peer-reviewed articles cover conventional procedures as well as newer clinical techniques.
For more information on VentriPoint’s leading-edge cardiac diagnostic technology, visit www.VentriPoint.com
Today's Top 3
Investor News Source
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Advaxis, Inc. (ADXSD) Updates Business Outlook for 2013
- Consorteum Holdings, Inc. (CSRH) Appoints Olde Monmouth Stock Transfer Company as New Transfer Agent
- Cardium Therapeutics, Inc. (CXM) Completes Preferred Stock Financing
- DoMark International, Inc. (DOMK) Purchases 20% of Zaktek Ltd.
- Epazz Inc. (EPAZ) Announces Second Planned Spin-Off Project "Human Power" Mobile Power Device
- GlobalWise Investments, Inc. (GWIV) Launches Intelli-Cloud(TM), a New Cloud-Based Service Offering
- GNCC Capital, Inc. (GNCP) Completes the Acquisition of the White Hills Gold Properties
- International Stem Cell Corp. (ISCO) Announces Pricing of Public Offering
- Mabwe Minerals Inc. (MBMI) Commences Mining Operations at Dodge Mine
- Players Network (PNTV) Launches Las Vegas Lifestyle Channel and Social Community
- Rafarma Pharmaceuticals, Inc. (RAFA) Announces Cooperative Effort With Christian Albrecht University in Kiel, Germany
- Rainbow Coral Corp. (RBCC) Insurance Companies, Researchers Drive Growth in Personalized Medicine
- Raptor Resources Holdings Inc. (RRHI) Mabwe Minerals Commences Mining Operations at Dodge Mine
- Solar Wind Energy Tower, Inc. (SWET) Receives Equity Facility Agreement Commitment of $3M
- StreamTrack, Inc. (STTK) RadioLoyalty Signs TargetSpot
- The Aristocrat Group Corp. (ASCC) Targets Lucrative Markets With Pending Distribution Deal
- VentriPoint Diagnostics Ltd. (VPTDF) University of Chicago Publishes First Results Using Ventripoint Heart Analysis System in Pulmonary Arterial Hypertension in Prestigous Medical Journal
- VistaGen Therapeutics, Inc. (VSTA) Provides Update on $36 Million Strategic Financing Agreement